rs1051296 — SLC19A1 SLC19A1 variant (RFC1)

SLC19A1 rs1051296 — The Folate Carrier's Silent Regulator

SLC19A1 — also known as RFC1 (reduced folate carrier 1) — is the primary gateway through which folate enters your cells. Without efficient RFC1 function, even a diet rich in folate or supplementation with folic acid may not fully replenish cellular folate stores, because the transporter is the rate-limiting step between circulating folate and the intracellular methylation machinery. The rs1051296 variant sits in the 3' untranslated region ¹¹ The 3'UTR is the sequence after the stop codon in messenger RNA; it controls mRNA stability and is a binding site for regulatory microRNAs of SLC19A1 and influences how strongly a microRNA called miR-595 can suppress RFC1 production.

The Mechanism

The rs1051296 variant creates or disrupts a binding site for miR-595²² miR-595
A regulatory microRNA that binds to the 3'UTR of target mRNAs and reduces their translation into protein. The A allele (reported on the plus strand; equivalent to T on the coding strand used in most papers) is the sequence that miR-595 recognizes. When miR-595 binds, it reduces SLC19A1 messenger RNA translation, lowering the amount of RFC1 transporter protein at the cell surface. The C allele (equivalent to G on the coding strand) disrupts this binding site — miR-595 cannot bind as effectively, so RFC1 levels remain higher. The net result is that AA homozygotes have meaningfully lower RFC1 expression than CC homozygotes, with AC heterozygotes in between.

The Evidence

The functional mechanism was established in a 2014 pharmacogenomic study of 131 Chinese children with acute lymphoblastic leukemia³³ 2014 pharmacogenomic study of 131 Chinese children with acute lymphoblastic leukemia
Wang SM et al. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with ALL. Med Oncol. 2014. Methotrexate is a folate antagonist transported into cells almost exclusively by RFC1, making it an ideal pharmacological probe for transporter function. Children with the AA genotype (plus strand) had average 24-hour methotrexate plasma levels of 29.97 µmol/L, compared to 39.01 µmol/L for CC homozygotes. More strikingly, only 8.6% of AA carriers achieved the therapeutic threshold of >40 µmol/L, versus 40.0% of CC carriers (p=0.02). This disparity reflects reduced cellular uptake rather than a kinetic elimination difference — AA carriers retain more methotrexate in plasma because less enters cells.

The 2018 mechanistic study⁴⁴ 2018 mechanistic study
Wang SM et al. MiR-595 suppresses the cellular uptake and cytotoxic effects of methotrexate by targeting SLC19A1. Basic Clin Pharmacol Toxicol. 2018 confirmed the molecular basis using luciferase reporter assays. Introducing miR-595 mimics into leukemia cell lines caused a significant drop in SLC19A1 reporter activity only when the A-allele 3'UTR was present (p<0.01), demonstrating direct miR-595 binding at this site. miR-595 overexpression also reduced RFC1 protein levels, intracellular methotrexate accumulation, and drug-induced cytotoxicity.

Beyond pharmacogenomics, a 2025 case-control study⁵⁵ 2025 case-control study
Nasir I et al. SLC19A1 Gene Polymorphism; Risk Factor for Preeclampsia. J Coll Physicians Surg Pak. 2025 in 332 Pakistani women found that the CA and AA genotypes were associated with significantly elevated preeclampsia risk (p<0.03 and p<0.001 respectively), while the CC genotype appeared protective. Folate adequacy compounded the genotype effect: women with the CA genotype and low circulating folate had the highest preeclampsia susceptibility. This finding is biologically plausible given the critical role of one-carbon metabolism in placental function and maternal vascular health.

Practical Actions

The most direct implication of reduced RFC1 transport efficiency is that dietary and supplemental folate may require higher intake or more bioavailable forms to achieve the same intracellular concentration as in CC carriers. Since methotrexate uses the same transporter, AA carriers receiving methotrexate therapy may need dose adjustments to achieve therapeutic drug levels — this should be discussed with the prescribing physician. For those planning or carrying a pregnancy, ensuring adequate active folate intake is especially important given the preeclampsia association.

Interactions

rs1051296 interacts biologically with rs1051266 (SLC19A1 G80A, the missense variant at codon 27 of RFC1). rs1051266 affects the transporter's affinity for folate substrates, while rs1051296 affects the amount of transporter expressed. Carrying reduced-function alleles at both sites compounds the transport deficit. Both variants also interact with MTHFR variants (rs1801133 C677T, rs1801131 A1298C): impaired folate delivery (SLC19A1) combined with impaired folate utilization (MTHFR) creates a compounding one-carbon cycle burden, with potential for elevated homocysteine and reduced methylation capacity even at dietary folate intakes considered adequate for most people.